Clinical Trial Update: Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy and safety of oral controlled-release nicotinic acid (CIR-NA) for remission of prediabetes. The study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prediabetes

Drugs mentioned

• CIR-NA (nicotinic acid)

Snippet

Sponsor: University Hospital Schleswig-Holstein | Conditions: Prediabetes (Insulin Resistance, Impaired Glucose Tolerance) | Phase 2 | Status: RECRUITING